Clear cell variants of transitional cell carcinomas (TCC) of the bladder are extremely rare tumors. Only 6 cases have been reported until now. We report of a 67 year old man who presented with fast growing tumor disease. While initial diagnosis showed localized bladder tumor, final histopathology revealed pT4, G3, L1 urothelial carcinoma with clear cell differentiation. No more than 14 weeks after initial diagnosis the patient died from multi-organ failure after unsuccessful salvage laparotomy which showed massive tumor burden within the pelvis and peritoneal carcinosis. This case demonstrated an extremely fast tumor growth. Therefore, patients with clear cell urothelial carcinoma should be treated vigorously and without time delay. We present a case of clear cell variant of TCC which exhibited an extremely aggressive behavior. To our knowledge this is the fifth report of this rare disease.
Introduction
Approximately 15% of carcinomas of the bladder account for variants other than the most common urothelial carcinoma. The four major categories are squamous cell carcinoma, adenocarcinoma, undifferentiated carcinoma and variants of urothelial carcinoma. 1 Within the latter category, squamous, trophoblastic, glandular, micropapillary, nested and small cell differentiation are well described. However, little is known about urothelial carcinoma of the bladder with clear cell differentiation.
Case Report
A 65-year-old white male presented with progressive lower urinary tract symptoms and worsening of general condition. His past medical history was unremarkable. Laboratory investigation revealed elevated serum creatinine levels (139 mmol/L). Ultrasonography showed III pyelocaliectasia on both kidneys, thickening of the urinary bladder wall as well as residual urine of appr. 500 mL. Blood prostate specific antigen (PSA) level: 2.5 mg/L. After insertion of an indwelling urinary catheter creatinine levels did not decrease and the pyelocaliectasia remained. The patient underwent cystoscopy. Distal ureteral stenoses on both sides were recognized and ureteral stents were inserted. Non-papillary, solid tumor masses were found on the vesical trigonum and were removed by transurethral resection (TURBt). The pathohistological examination revealed poorly differentiated urothelial carcinoma of the clear cell variant with detrusor muscle infiltration (pT2a, G3). Computed tomography (CT) scan demonstrated 14 mm bladder wall thickening, no tumor invasion in perivesical tissue and no evidence of metastasis ( Figure 1 ). Shortly after diagnosis, the patient was scheduled for radical cystectomy and ileal conduit. . Clear cell variant of urothelial cancer is a very rare subtype of glandular neoplasms to which also adenocarcinoma must be mentioned. A limited number of cases have been reported up to date; [2] [3] [4] [5] this is the fifth report of this rare variant of transitional cell carcinomas ( Table 1 ). The problematic feature of clear cell variant urothelial carcinoma can be approached from two directions: histopathologically and clinically. Clear cell carcinoma can arise in almost any site including prostate, kidneys, uterus, ovary, vagina, lung and breast. [6] [7] [8] [9] Therefore it might be difficult to diagnose the primary site. Based on the urinary tract, clear cell features within the bladder have been mostly associated with adenocarcinomas that have been reported to be more frequent than clear cell variant urothelial carcinomas. The histopathology in our patient revealed multiple layers and severe nuclear atypia in an alveolar growth pattern (Table 2, Figure 2 ). Typical pattern of adenocarcinomas of the bladder such as glandular differentiation, tubulocystic or papillary morphological patterns as well as hobnail cells were not observed. Although not being a clear feature for differentiation immunohistochemical positivity for CK7 might suggest an urothelial ori- The clinical course of clear cell variant urothelial carcinomas of the bladder is currently unknown due to the lack of larger case series. Only five cases with clinical information have been published (Table 1) . [2] [3] [4] [5] Our patient showed aggressive behavior with rapid local recurrence and development of peritoneal carcinosis to which he succumbed only 14 weeks after initial diagnosis at which an advanced tumor stage had been not assumed. A similar clinical course has been described by Kotliar and colleagues. 4 They reported of a 71-year old male who underwent radical cystoprostatectomy with ileal conduit due to muscle-invasive urothelial carcinoma clear-cell variant. Although computed tomography revealed no evidence of pelvic lymphadenopathy, nor metastatic disease, two pelvic lymph nodes were diagnosed carcinoma-positive. In spite of adjuvant chemotherapy the patient died after 20 months. In contrast a less aggressive course has been reported in two patients with urothelial clear cell carcinoma who were treated with TURBt, even though one patient had detrusor muscle invasion. 3, 5 Both patients Case Report Table 2 . Microscopic evaluation of each case. Common findings are glycogen-rich cytoplasm and nuclear atypia. In contrast to adenocarcinomas of the bladder glandular differentiation and hobnail cells are not found.
Report Cases Microscopic findings
Kotliar et al. were free from recurrence after 7 and 20 months (Table 1 ).
In conclusion, clear-cell variant urothelial carcinoma is a rare pathologic finding with a variable clinical course. Adenocarcinoma of the bladder, the major differential diagnosis, can be discriminated by conventional histology and immunohistochemistry. Clear-cell variant urothelial carcinoma shows a glycogen-rich cytoplasm and may be either circumscribed or extensive whereas adenocarcinoma is characterized by glandular differentiation and hobnail cells. Up to date immunohistochemical staining does not help to differentiate both variants (Table 3) . Therefore, the pathologist is urged to make a decision based on microscopic findings. Future attempts should strive for strict diagnostic criteria as a prerequisite to define the underlying biology/genetic defects. Lager series are needed to classify prognostic groups and to choose the best therapeutic options for this rare tumor entity. 
